Calcific uraemic arteriolopathy: an update

Area of Science:

• Nephrology
• Vascular Biology
• Dermatology

Background:

• Calcific uraemic arteriolopathy (CUA), or calciphylaxis, is a rare yet significant cause of mortality in chronic kidney disease (CKD) patients.
• The incidence of CUA is rising among individuals with renal failure and is increasingly observed in non-uraemic populations.
• Understanding the molecular mechanisms of vascular calcification, particularly the uraemic microenvironment's role in smooth muscle cell differentiation into osteoblasts, is advancing.

Purpose of the Study:

• To review the current understanding and emerging treatments for calcific uraemic arteriolopathy (CUA).
• To highlight new therapeutic options for managing hyperphosphatemia and secondary hyperparathyroidism in CKD patients with CUA.
• To discuss established and novel treatment modalities for CUA.

Main Methods:

• Review of recent literature on CUA pathophysiology and treatment.
• Analysis of emerging therapies for mineral bone disorder in CKD.
• Evaluation of non-traditional CUA treatments.

Main Results:

• New treatments for hyperphosphatemia and secondary hyperparathyroidism, including bisphosphonates, novel phosphate binders, and cinacalcet, are being explored for CUA.
• Alternative CUA treatments such as hyperbaric oxygen and sodium thiosulphate show promise.
• The molecular basis of vascular calcification in CUA is increasingly understood, emphasizing the uraemic microenvironment's role.

Conclusions:

• A combined therapeutic strategy for CUA is recommended, integrating management of calcium/phosphate derangements with wound healing modalities.
• Newer agents for mineral homeostasis and established treatments like hyperbaric oxygen and sodium thiosulphate infusions should be considered.
• A significant lack of randomized controlled trials for CUA treatments persists, necessitating further research.